SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
I recently attended a healthcare related event that featured a panel discussion comprised of life science bankers and venture capitalists. While members of this panel often had differing viewpoints, they did mutually agree they were interested in emerging therapeutic candidates that provided more than one "shot on goal," meaning the possibility of a single therapy that could address more than one disease indication.
In the case of the Aethlon Hemopurifier®, we have created a therapeutic filtration device that selectively captures a broad-spectrum of disease promoting particles from circulation without eliminating blood components required for health. However, instead of immobilizing an antibody or agent that specifically binds to a single pathogen, we made the bold decision to deploy the capabilities of a lectin affinity agent that binds to a unique structure evolved and shared by viruses and cancer as a survival mechanism that allows disease progression to continue below the surveillance of the immune system. In the treatment of Hepatitis C virus (HCV), we have demonstrated that our Hemopurifier® can eliminate the presence of HCV in as little a seven days when utilized in combination with interferon-based therapy. Short-term administration of the same device has reduced viral load by greater than 90% in an HIV-AIDS dialysis patient who was not receiving any form of antiviral drug therapy. Additionally, government and non-government research organizations have demonstrated the Hemopurifier® captures a wide range of bioterror and pandemic threats. In regards to cancer, the same Hemopurifier® deployed in infectious disease studies has emerged to be the first therapeutic strategy to address tumor-secreted exosomes. Tumor-secreted exosomes are a vital therapeutic target as they have recently been discovered to be immunosuppressive and play significant role in seeding the creation and spread of cancer metastasis.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts